Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl

European Journal of Clinical Pharmacology

Volumn 64, Issue 1, 2008, Pages 25-30

  Saari, Teijo I ^a   Laine, Kari ^a   Neuvonen, Mikko ^b   Neuvonen, Pertti J ^b   Olkkola, Klaus T ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

CYP3A; Cytochrome P450; Fentanyl; Fluconazole; Pharmacokinetics; Voriconazole

Indexed keywords

CYTOCHROME P450 3A4; DRUG METABOLITE; FENTANYL; FLUCONAZOL; FLUCONAZOLE; NALOXONE; NARCOTIC ANALGESIC AGENT; NORFENTANYL; UNCLASSIFIED DRUG; VORICONAZOLE;

ABSENCE OF SIDE EFFECTS; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CROSS REACTIVITY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; OPEN STUDY; PLASMA CLEARANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATION DEPRESSION; STATISTICAL ANALYSIS; VOLUNTEER;

ADMINISTRATION, ORAL; ANALGESICS, OPIOID; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; FENTANYL; FLUCONAZOLE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; PYRIMIDINES; TISSUE DISTRIBUTION; TRIAZOLES;

EID: 38049041555     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-007-0398-x     Document Type: Article

References (33)

1. Muijsers RB, Wagstaff AJ (2001) Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs 61(15):2289-2307
2. Mystakidou K, Katsouda E, Parpa E, Vlahos L, Tsiatas ML (2006) Oral transmucosal fentanyl citrate: overview of pharmacological and clinical characteristics. Drug Deliv 13(4):269-276
3. Portenoy RK, Messina J, Xie F, Peppin J (2007) Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study. Curr Med Res Opin 23(1):223-233
4. Tateishi T, Krivoruk Y, Ueng YF, Wood AJ, Guengerich FP, Wood M (1996) Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation. Anesth Analg 82(1):167-172
5. Guitton J, Buronfosse T, Desage M, Lepape A, Brazier JL, Beaune P (1997) Possible involvement of multiple cytochrome P450S in fentanyl and sufentanil metabolism as opposed to alfentanil. Biochem Pharmacol 53(11):1613-1619
6. Labroo RB, Paine MF, Thummel KE, Kharasch ED (1997) Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions. Drug Metab Dispos 25(9):1072-1080
7. Ibrahim AE, Feldman J, Karim A, Kharasch ED (2003) Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. Anesthesiology 98(4):853-861
8. Bower S, Hull CJ (1982) Comparative pharmacokinetics of fentanyl and alfentanil. Br J Anaesth 54(8):871-877
9. Rowland M, Tozer TN (1995) Elimination. In: Rowland M, Tozer TN (eds) Clinical pharmacokinetics: concepts and applications. 3rd edn. Williams and Wilkins, Baltimore, pp 156-183
10. Olkkola KT, Palkama V, Neuvonen PJ (1999) Ritonavir's role in reducing fentanyl clearance and prolonging its half-life. Anesthesiology 91(3):681-685
11. Theuretzbacher U, Ihle F, Derendorf H (2006) Pharmacokinetic/ pharmacodynamic profile of voriconazole. Clin Pharmacokinet 45(7):649-663
12. Hyland R, Jones BC, Smith DA (2003) Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metabol Dispos 31(5):540-547
13. Hynninen VV, Olkkola KT, Leino K, Lundgren S, Neuvonen PJ, Rane A, Valtonen M, Vyyrylainen H, Laine K (2006) Effects of the antifungals voriconazole and fluconazole on the pharmacokinetics of s-(+)- and R-(-)-Ibuprofen. Antimicrob Agents Chemother 50(6):1967-1972
14. Romero AJ, Le Pogamp P, Nilsson L-G, Wood N (2002) Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther 71(4):226-234
15. Saari TI, Laine K, Leino K, Valtonen M, Neuvonen PJ, Olkkola KT (2006) Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Clin Pharmacol Ther 79(4):362-370
16. Saari TI, Laine K, Leino K, Valtonen M, Neuvonen PJ, Olkkola KT (2006) Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life. Clin Pharmacol Ther 80(5):502-508
17. Morita K, Konishi H, Shimakawa H (1992) Fluconazole: a potent inhibitor of cytochrome P-450-dependent drug-metabolism in mice and humans in vivo. Comparative study with ketoconazole. Chem Pharm Bull (Tokyo) 40(5):1247-1251
18. Wienkers LC, Wurden CJ, Storch E, Kunze KL, Rettie AE, Trager WF (1996) Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19. Drug Metab Dispos 24(5):610-614
19. Niwa T, Shiraga T, Takagi A (2005) Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull 28(9):1805-1808
20. Olkkola KT, Ahonen J, Neuvonen PJ (1996) The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg 82(3):511-516
21. Varhe A, Olkkola KT, Neuvonen PJ (1996) Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism. Br J Clin Pharmacol 41(4):319-323
22. Palkama VJ, Isohanni MH, Neuvonen PJ, Olkkola KT (1998) The effect of intravenous and oral fluconazole on the pharmacokinetics and pharmacodynamics of intravenous alfentanil. Anesth Analg 87(1):190-194
23. Hallberg P, Marten L, Wadelius M (2006) Possible fluconazole-fentanyl interaction-a case report. Eur J Clin Pharmacol 62(2):491-492
24. Gage R, Stopher DA (1998) A rapid HPLC assay for voriconazole in human plasma. J Pharm Biomed Anal 17(8):1449-1453
25. Pennick GJ, Clark M, Sutton DA, Rinaldi MG (2003) Development and validation of HPLC assay for voriconazole. Antimicrob Agents Chemother 47(7):2348-2350
26. Inagaki K, Takagi J, Lor E, Okamoto MP, Gill MA (1992) Determination of fluconazole in human serum by solid-phase extraction and reversed-phase high-performance liquid chromatography. Ther Drug Monit 14(4):306-311
27. Akaike H (1976) An information criterion (AIC). Math Sci 14:5-9
28. Wagner JG (1976) Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data. J Pharmacokin Biopharm 4(5):443-467
29. McClain DA, Hug CC (1980) Intravenous fentanyl kinetics. Clin Pharmacol Ther 28(1):106-114
30. Kharasch ED, Whittington D, Hoffer C (2004) Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate. Anesthesiology 101(3):729-737
31. Handal KA, Schauben JL, Salamone FR (1983) Naloxone. Ann Emerg Med 12(7):438-445
32. Jung BF, Reidenberg MM (2005) Interpretation of opioid levels: comparison of levels during chronic pain therapy to levels from forensic autopsies. Clin Pharmacol Ther 77(4):324-334
33. Grond S, Radbruch L, Lehmann KA (2000) Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl. Clin Pharmacokinet 38(1):59-89